Source: Fox News
Summary
A recent review of 26 clinical trials suggests that a single intravenous ketamine infusion can provide rapid relief for patients with severe depression and suicidal symptoms. The study found that ketamine significantly reduced depression in just four hours and lowered suicidal thoughts within 24 hours. Patients reported fewer depressive symptoms after a week and reduced suicidal thoughts for up to a month after one ketamine infusion. The researchers note that ketamine is not a panacea and should only be used medically under careful supervision due to its potential risks.
Our Reading
The recommendation enters another phase.
Ketamine, originally developed as an anesthetic, has been found to reduce pain and help treat depression. However, it can also be misused as a recreational drug. The review of 26 clinical trials included over 1,100 patients, with approximately 626 receiving ketamine and 540 serving as controls. The study found that ketamine significantly reduced depression and suicidal thoughts in just a few hours. The effects of a single ketamine infusion are relatively short-lived, and patients with treatment-resistant depression may need repeated sessions. The researchers note that ketamine is not yet FDA-approved for treating depression, but it may still be used with off-label indications for those with severe depression and/or a high risk of suicidal behaviors.
The advice sounds familiar, as ketamine has been studied for its potential antidepressant effects in the past. The current study provides further evidence for its rapid relief of depressive symptoms, but also highlights the need for careful medical supervision due to its potential risks.
As one expert noted, “When all existing treatment options fail, patients with severe depression could consider ketamine infusions.” This sentiment is echoed by another expert, who stated that ketamine can be “genuinely lifesaving” for a small subset of patients struggling with suicidal thoughts.
However, it’s worth noting that the study’s findings are not without limitations, including the small sample size and the potential for patients to have realized they were receiving ketamine, which could have influenced their reported symptoms.
The situation is a reminder that depression treatment is not a one-size-fits-all solution, and what works for one patient may not work for another.
As the researchers concluded, “While long-term outcomes have not been studied, I believe that when patients are severely depressed or suicidal, ketamine is sometimes the only choice that almost always works.”
It’s a sentiment that feels slightly uncomfortable because it feels familiar – the search for a quick fix, the reliance on a single treatment, and the hope for a miracle cure.
Author: Evan Null
